Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Control Bionics Ltd. ( (AU:CBL) ) just unveiled an announcement.
Control Bionics reported a strategically significant December 2025 quarter highlighted by a $3.8 million capital raise to fund commercial, regulatory and manufacturing initiatives across its core platforms, including NeuroNode and NeuroStrip, in the US and Australian markets. The company advanced its NeuroNode distribution strategy through trials with US organisations and, shortly after the quarter, signed a distribution partnership with Tobii, the global AAC leader, while also becoming one of the first organisations to integrate with Apple’s brain–computer interface protocol, reinforcing its technology leadership and enabling closer alignment with mainstream consumer platforms. Control Bionics completed the acquisition of Neuro Elite Athletics (NeuroBounce), creating a dedicated base for its sports performance program and expansion into elite sport, rehabilitation and broader performance markets, and continued the rollout of NeuroStrip, securing usage agreements with high-profile institutions such as the Australian Institute of Sport, Melbourne Victory, Ohio University, The Mayo Clinic, Mountain Land Physical Therapy and The Burrows Institute, supported by the commencement of scaled manufacturing. Quarterly cash receipts were steady at $1.4 million versus a year earlier, with revenue constrained by industry-wide delays in Australia’s NDIS approvals, but the company indicated underlying demand remains robust and said these strategic moves position it well for execution and growth through 2026.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.
More about Control Bionics Ltd.
Control Bionics Limited is an Australian-listed neurotechnology company focused on non-invasive brain–computer interface and assistive communication solutions. Its core products include the NeuroNode system for augmentative and assistive communication (AAC), the NeuroStrip sensor platform for sports performance and rehabilitation, and a growing sports-focused business via NeuroBounce, with key markets in the United States and Australia.
Average Trading Volume: 1,114,254
Technical Sentiment Signal: Buy
Current Market Cap: A$28.43M
Learn more about CBL stock on TipRanks’ Stock Analysis page.